J a n u a r y 20 1 8
SAB Team & Technology – Together for 15+ Years Technology Purchased by SAB Biotherapeutics originated at the Kirin Pharma, begins independent University of BioDak Acquires IP, operations Massachusetts Kyowa Hakko Kirin @ Amherst merger 2005 - 2010 2014 - 2016 1998 2000 - 2005 2010 - 2014 2016 - 2017 Sullivan becomes CEO, Sanford Applied Hamilton investment, Biosciences acquires Phase 1 headquarters moved to team and IP Clinical Trials Begin, Sioux Falls, Sanford Applied Construction Human antibodies Biosciences & BioDak begins on pharm from cloned cattle Merge DECEMBER 2017 2
Accomplished Leadership Team Expertise in development, regulatory, vaccinology and cGMP production Eddie J. Sullivan, PhD Edward Hamilton, DVM Charles Randall, Jr. PRESIDENT & CEO / CO-FOUNDER EXECUTIVE CHAIRMAN BOD / CO - CHIEF FINANCIAL OFFICER, EVP FOUNDER Christoph Bausch, PhD Jerry Pommer, MSc, PAS Hua Wu, PhD CHIEF SCIENCE OFFICER CHIEF COMPLIANCE OFFICER SENIOR SCIENTIST PRODUCT DEVELOPMENT & SVP REGULATORY & QUALITY SVP VACCINE & ANTIBODY MANUFACTURING ASSURANCE DEVELOPMENT DECEMBER 2017 3
New Source for Natural Proven Treatment DiversitAb TM fully-human polyclonal antibodies offer the benefits without the issues PLASMA OR SERUM SOURCES ANIMAL ANTIBODIES HUMAN ANTIBODIES BLOOD DONOR Unique Patient Antigen TC BOVINE HORSES GOATS RABBITS HUMANS SERUM CLOT Truncated Poor safety Small Limited High antibodies profile volume amount Diversity Very short acting Tolerate limited Safety concerns Difficult to No Immunogenicity doses of drug for multiple doses “target” Rapidly Scalable TOXIN SNAKE TRANSPLANT VIRAL ALL BLOOD SERUM CONTAINING EXPOSURE VENOM REJECTION INFECTION APPLICATIONS POLYCLONAL ANTIBODIES DECEMBER 2017 4
Only Scalable Human Polyclonal Immunotherapy Platform DIVERSITAB™ PLATFORM The proprietary platform can rapidly develop and manufacture fully human polyclonal antibodies Tc Bovine TM Immunization Plasmapheresis Purification Antibody Therapeutic Cows genetically designed Tc Bovine vaccinated with Antibodies harvested Separates antibodies For use as human treatment to produce human antibodies target disease antigen in the form of plasma from plasma or prophylaxis Upstream Process Downstream Process (industry standard) *MATSUSHITA H, SANO A, WU H, WANG Z, JIAO J-A, KASINATHAN P, ET AL. (2015) SPECIES-SPECIFIC CHROMOSOME ENGINEERING GREATLY IMPROVES FULLY HUMAN POLYCLONAL ANTIBODY PRODUCTION PROFILE IN CATTLE. PLOS ONE 10(6): E0130699. DOI:10.1371/JOURNAL.PONE.0130699 DECEMBER 2017 5
cGMP product can be produced 75 days after first vaccination Condensed development timeline for application on multiple targets RAPID FULLY HUMAN PABS PRODUCT TIMELINE PRODUCT DEVELOPMENT 1 2 3 4 5 Tc Bovine Vaccination 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 WEEK Plasma Collection V2D8 V1DAY0 V3D8 V4D8 V5D8 V2D11 V3D11 V4D11 V5D11 V2D14 V2D14 V4D14 V5D14 Manufacture 2 WEEKS Quality Control Test 3 WEEKS Quality Assurance Review 2-3 WEEKS DECEMBER 2017 6
Antibody Production Facilities Many targets from one platform with capacity of 1 million doses/year( ~60-80 animals) Tc Bovine TM Plasmapheresis Manufacturing produce targeted collects antibodies is cGMP industry human antibodies. in donated plasma. standard process. SAB’s immunotherapy Animals produce 30-60 Immunotherapy platform platform targets a virus, liters per month per animal, targets a virus, bacteria, or bacteria, or toxin, generating providing rapid scalability. toxin, generating high titer, high titer, high affinity, The disease targeted high affinity, human human immunoglobulin for plasma is then sent to immunoglobulin for monovalent or multivalent manufacturing for monovalent or multivalent targets. purification and fill finish. targets. > PLASMA STABLE FOR 10 YRS. DECEMBER 2017 7
Integrating Operations with New Production Facility First-of-its kind greenfield biological pharm provides infrastructure for growth PHARM IS KEY COMPONENT TO OWNING THE ENTIRE SUPPLY CHAIN Office, surgery, nursery & grower building completed Q1 2018 THE PHARM, AN AGRICULTURAL-BASED PRODUCTION UNIT WHOSE OUTPUT IS BIOLOGICALS FOR THE BENEFIT OF HUMAN HEALTH, IS THE FIRST FACILITY OF ITS KIND DESIGNED SPECIFICALLY FOR CATTLE. THE GREENFIELD CONSTRUCTION PHASE HOUSES CURRENT PRODUCTION ANIMALS WITH INFRASTRUCTURE TO GROW TEN-FOLD 8 DECEMBER 2017
Scalability = 2,500,000 - 5,000,000 doses / year 20% of pharm production capacity could supply entire seasonal influenza market Tc Bovine – Barn 1 12.08.17 New cGMP manufacturing facilities in development THE 80-ACRE BIOPHARMACEUTICAL PRODUCTION PHARM AT FULL BUILD-OUT WILL HOUSE APPROXIMATELY 400 ANIMALS AND EMPLOY 40 PEOPLE. DECEMBER 2017 9
Tc Bovine at Pharm1 (P1) First wing of first barn complete and housing production animals. THE 80-ACRE BIOPHARMACEUTICAL PRODUCTION PHARM AT FULL BUILD-OUT WILL HOUSE APPROXIMATELY 400 ANIMALS AND EMPLOY 40 PEOPLE. DECEMBER 2017 10
Investor Value Proposition MULTIPLE REVENUE STREAMS, EQUITY OPPORTUNITIES CASH & EQUITY PRODUCING & EXITS SPECIAL PURPOSE ENTITIES (SPE) DEFINED MARKET & GOVERNANCE / SIGNIFICANT SAB EQUITY / EXIT OPPORTUNTIES SPECIALIZED EXPERTISE / ABILITY TO MODEL VALUE / 3RD PARTY INVESTMENT PRODUCT TARGETS ($100B+ MARKET) MRSA $500M/YR DiversitAb ™ Platform Cancer $Bs/YR LARGE ACCESSIBLE MARKETS ADVANCED SKILL SETS ATG • Infectious Disease • cGMP Manufacturing • Oncology • Clinical Regulatory $800M/YR • Autoimmune • Animal Management • Toxins • Intellectual Property Influenza SPE • Anti-Microbial Resistance • R&D $1B/YR SPE’s CAN CAPITAL STRATEGY CASH FLOW & EQUITY CAPITALIZE & REVENUE MODEL FROM PRODUCT SPE’S PLATFORM • Retain All IP in Platform • No Restrictions on New Programs GROWTH • Retain Manufacturing Revenue • Ability to Develop To Larger Value Inflection • No Limit to SPE’s • Flexibility - Retain any Portion of Value DECEMBER 2017 11
SAb Funding Strategy Milestones for Funding 1. Clinical Data Most Important Driver 2. Funding from Recognized Partner DTI, Inc. SAb Platform Annual Funding to Growth Funding to Cover Commercial/Strategic Partner Cover $6M Burn Rate Expansion $100M Req that is Recognized in Industry $6.6M at $70M 2014 2015 2016 $4.5M at $125M 2017 Helpful $12M at $157M Term Sheet $30M 2018 $??M at $???M 2019 2020 Phase 2 Date $100M
Company Value Increase $180,000,000 $160,000,000 $140,000,000 $120,000,000 $100,000,000 $80,000,000 $60,000,000 $40,000,000 $20,000,000 $- Hematech Series A Stock Buyback LFB Term Sheet Series A1 Series A2 2005 2014 2015 2016 2017 2018
Stock Value Increase $3.50 $3.00 $2.50 $2.00 $1.50 $1.00 $0.50 $0.00 Hematech Series A Stock Buyback LFB Term Sheet Series A1 Series A2 2005 2014 2015 2016 2017 2018
14% Common 7% Series A 4% Series A-1 63% 12% Series A-2 Options
SPEs Profit Platform Centers Investors A, A-1, A-2 Mkt License Only Separate BOD Dakota Ag SAb Biotherapeutics, Inc. 3rd Party Ventures, LLC Investors BOD Controlled, Platform Investors Financing Entity 7% Equity SAB, LLC Cost Centers IP Holding Single Member DTI, Inc QA/QC Recip Herd Tc Bovine Joint Venture, Equity Prod’t Pharm Cloning Lab cGMP Mfg Tc Capra Ag Prod’t Prod’t Pharm Tc Bovine & Lab R & D Capra SPEs 100% Equity SAB Capra, LLC SG&A Grant Funding Entity Single Member Revenue/Grants Product Cost Equity Capital Upstream Process Downstream Process Midstream Process Lic/Control
Recommend
More recommend
